Unlike EGFR mutations, which are a positive prognostic factor, KRAS mutations in resected NSCLC were associated with shorter overall survival than those with EGFR mutations [17], [18], [19]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.